Palm Oil and Beta-palmitate in Infant Formula: A Position Paper by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Committee on Nutrition
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, systematický přehled
PubMed
31022096
DOI
10.1097/mpg.0000000000002307
PII: 00005176-201905000-00028
Knihovny.cz E-zdroje
- MeSH
- fyziologie výživy kojenců MeSH
- gastroenterologie organizace a řízení MeSH
- kojenec MeSH
- kyselina palmitová krev MeSH
- lidé MeSH
- mateřské mléko chemie MeSH
- náhražky mateřského mléka chemie MeSH
- novorozenec MeSH
- nutriční stav MeSH
- palmitany aplikace a dávkování MeSH
- palmový olej aplikace a dávkování MeSH
- pediatrie organizace a řízení MeSH
- potravní doplňky MeSH
- společnosti lékařské MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- systematický přehled MeSH
- Názvy látek
- kyselina palmitová MeSH
- palmitany MeSH
- palmový olej MeSH
BACKGROUND: Palm oil (PO) is used in infant formulas in order to achieve palmitic acid (PA) levels similar to those in human milk. PA in PO is esterified predominantly at the SN-1,3 position of triacylglycerol (TAG), and infant formulas are now available in which a greater proportion of PA is in the SN-2 position (typical configuration in human milk). As there are some concerns about the use of PO, we aimed to review literature on health effects of PO and SN-2-palmitate in infant formulas. METHODS: PubMed and Cochrane Database of Systematic Reviews were systematically searched for relevant studies on possible beneficial effects or harms of either PO or SN-2-palmitate in infant formula on various health outcomes. RESULTS: We identified 12 relevant studies using PO and 21 studies using SN-2-palmitate. Published studies have variable methodology, subject characteristics, and some are underpowered for the key outcomes. PO is associated with harder stools and SN-2-palmitate use may lead to softer stool consistency. Bone effects seem to be short-lasting. For some outcomes (infant colic, faecal microbiota, lipid metabolism), the number of studies is very limited and summary evidence inconclusive. Growth of infants is not influenced. There are no studies published on the effect on markers of later diseases. CONCLUSIONS: There is insufficient evidence to suggest that PO should be avoided as a source of fat in infant formulas for health reasons. Inclusion of high SN-2-palmitate fat blend in infant formulas may have short-term effects on stool consistency but cannot be considered essential.
Childhood Nutrition Research Centre UCL GOS Institute of Child Health London UK
Children's Hospital Zagreb University of Zagreb School of Medicine Zagreb Croatia
CNRC Baylor College of Medicine Houston Texas
Department of Clinical Sciences Pediatrics Umeå University Umeå Sweden
Department of Neonatal Intensive Care Oslo University Hospital Oslo Norway
Department of Nutrition Exercise and Sports University of Copenhagen
Department of Paediatrics University Hospital Motol Prague Czech Republic
Department of Paediatrics University of Granada Spain
Leeds teaching hospitals NHS trust Leeds UK
Ospedale Pediatrico Giovanni XXIII University of Bari Bari Italy
Paris Descartes University APHP Necker Enfants Malades hospital Paris France
Pediatric Nutrition Unit Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Citace poskytuje Crossref.org